|
Variable
|
Categories
| |
Number of patients (%)*
|
|---|
|
Patients in study
| | |
53 (100)
|
|
Mesothelioma subtype
|
Epitheloid
| |
46 (87)
|
| |
Sarcomatoid
| |
1 (2)
|
| |
Biphasic
| |
5 (9)
|
| |
Unknown
| |
1 (2)
|
|
Sex
|
Male
| |
36 (68)
|
| |
Female
| |
17 (32)
|
|
Age
|
Mean
| |
69 (range 24–90)
|
|
Performance status
|
0
| |
4 (8)
|
| |
1
| |
28 (53)
|
| |
2
| |
6 (11)
|
| |
3
| |
2 (4)
|
| |
Unknown
| |
13 (25)
|
|
Chemotherapy lines including current
|
0
| |
14 (26)
|
|
1
| |
36 (68)
|
|
2
| |
2 (4)
|
|
3
| |
1 (2)
|
|
Chemotherapy status while on the study
|
Given
| |
30 (56.6)
|
| | |
Mesomark prior to CT
|
12 (40)
|
| | |
Mesomark post CT
|
18 (60)
|
| |
Not given
| |
23 (43)
|
- *Percentages rounded up to the nearest 1.0%; Mesomark, serum mesothelin ELISA test; CT, chemotherapy.
